Join our daily newsletter At The Bell to receive exclusive market insights
- BTC Health (BTC) is looking to raise $2.5 million in a capital raise to fund its investment in the Mannitol portfolio
- The company will issue shares to investors at 7 cents each
- Yesterday, BTC announced its investee company, BioImpact, acquired exclusive distribution rights for specialty respiratory brands Bronchitol and Aridol
- BTC entered a trading halt, meaning company shares will be paused until Monday, July 5, or when it completes the raise
- Company shares last traded at 7.4 cents per share
BTC Health (BTC) is looking at raising $2.5 million in a capital raise to fund its investment in the Mannitol portfolio.
Under the raise, the company will issue shares at 7 cents each to eligible investors.
Yesterday, BTC announced its investee company, BioImpact, acquired exclusive distribution rights for specialty respiratory brands Bronchitol and Aridol from Pharmaxis (PXS).
The exclusive distribution agreement is effective from today, July 1, with an initial term of 10 years.
Pharmaxis will continue to manufacture and supply Bronchitol and Aridol to BTC health from its facility in Sydney.
Bronchitol is used to treat cystic fibrosis and enables patients suffering from the disease to help clear mucus from the lungs.
Aridol is an innovative lung function test that is designed to help doctors diagnose and manage asthma.
BTC entered a trading halt, meaning company shares will be paused until Monday, July 5, or when it completes the raise.
Company shares last traded at 7.4 cents per share.
